Search

A recent report from the Western University of Health Sciences in Pomona, California discusses the management of dry eye disease (DED) with novel medications. DED is a common condition that primarily affects older individuals and women, characterized by reduced tear production and increased tear evaporation. The report reviews key trials of various new DED treatments, including their mechanism of action, study outcomes, safety, and efficacy. The research concludes that these FDA-approved novel medications exhibit safety and efficacy in managing DED, but further research is needed on long-term outcomes, efficacy, side-effect comparisons, and combination therapy benefits. [Extracted from the article]

Chemotherapy, Clinical Research, Clinical Trials and Studies, Drugs and Therapies, Health and Medicine, Pediatrics Keywords: Chemotherapy; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Health and Medicine; Pediatrics EN Chemotherapy Clinical Research Clinical Trials and Studies Drugs and Therapies Health and Medicine Pediatrics 685 685 1 06/05/23 20230605 NES 230605 2023 JUN 5 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on chemotherapy is now available. [Extracted from the article]

The article examines the landscape of repurposed medicines evaluated by non-commercial entities, focusing on identifying new uses for existing drugs to address unmet medical needs. Topics include the role of the NIHR Innovation Observatory in scanning clinical trial registries, the classification of 528 technologies for new indications, and the support for the NHS England Medicines Repurposing Programme.

The article discusses a study on the antimicrobial efficacy of nano-based intracanal medications conducted by Tanta University, published in the journal Clinical Trials Week on August 2, 2024. Topics include the evaluation of triple antibiotic-loaded chitosan nanoparticles and chlorohexidine loaded by silver nanoparticles on Enterococcus faecalis reduction, the study design involving randomized, double-masked intervention, and the anticipated outcomes related to bacterial count reduction.

A researcher at the University of Kragujevac in Serbia has published a review on the application of silicone in ophthalmology, specifically focusing on intraocular lenses (IOLs). Silicone is a synthetic polymer with excellent biocompatibility and hydrophobicity, making it suitable for various biomedical applications. The review discusses the physicochemical properties of silicone, methods for characterizing IOLs, biological aspects of posterior capsular opacification, and challenges and advancements in silicone IOLs. The study concludes that surface modifications of silicone IOLs can improve biocompatibility and enable drug-eluting functions, but further clinical trials are needed for these advanced technologies. [Extracted from the article]

Researchers from the National Institute of Health have proposed a reform on early access programs for medicines in Italy. The reform aims to create a single program inspired by the one introduced in France in 2021, allowing patients to access new medicines or indications before their official approval or reimbursement status. The proposal provides guidelines on eligibility criteria, application procedures, evaluation processes, economic safeguards, data collection, and implementation. This research was published in the Global & Regional Health Technology Assessment journal. [Extracted from the article]

A recent report discusses research findings on the potential benefits of polyphenols in disease prevention and therapy. Polyphenols are a group of phytochemicals found in various foods and drinks, such as fruits, cereals, tea, and coffee. Studies have shown that polyphenols possess antioxidant activities and therapeutic effects, and they may help prevent health problems like obesity, diabetes, cancer, and neurological diseases. The research concludes that a better understanding of polyphenols could lead to the development of polyphenol-rich diets and drugs, providing further evidence of their health benefits. [Extracted from the article]

A recent study from Kobe University in Japan discusses the importance of the colonic microbiota in human health and explores in vitro colonic microbiota culture models for evaluating the effects of functional ingredients on gut microbiota. The study introduces the Kobe University Human Intestinal Microbiota Model (KUHIMM), an innovative in vitro culture system that accurately reproduces the diversity of the colonic microbiota and metabolites in individual human donors. The researchers highlight the various applications of the KUHIMM, including assessing dietary fibers, probiotics, drugs, and herbal medicines. While the model has limitations, it is considered a valuable tool for research and development in predicting health effects and evaluating different drugs. [Extracted from the article]

Insilico Medicine, a biotechnology company, has announced the initiation of the first in-patient dose for ISM8207, a potential small molecule inhibitor targeting QPCTL, in collaboration with Fosun Pharma. The Phase I clinical trial, conducted in China, aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ISM8207 in patients with lymphoma and other advanced solid tumors. ISM8207 has shown promising results in preclinical studies, demonstrating a significant anti-tumor effect and a favorable in vitro and in vivo profile. This collaboration represents an important milestone in the development of innovative therapeutics for patients. [Extracted from the article]

A study conducted at Columbia University focused on improving antiretroviral therapy (ART) adherence among HIV-positive people who inject drugs (PWID) in Kazakhstan. The researchers implemented a dyad-based intervention, enrolling 66 HIV-positive PWID and their treatment support partners in a pilot randomized controlled trial. The intervention involved an adapted version of the SMART Couples intervention and utilized various implementation strategies such as remote delivery, staff training, and quality assurance. The study aimed to address the need for dyad-based ART adherence interventions specifically tailored for HIV-positive PWID. The research was supported by the NIH National Institute on Drug Abuse (NIDA) and has been peer-reviewed. [Extracted from the article]

A report from the University of Sydney discusses the efforts of the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee to improve drug use and develop new therapies for older adults. The committee proposes strategies for drug development and evaluation, emphasizing the need to consider age-related characteristics such as multimorbidity, polypharmacy, falls, cognitive impairment, and frailty. The report highlights the importance of measuring frailty in drug development and suggests the use of preclinical models that replicate the characteristics of older patients. The research concludes that involving older adults, caregivers, and healthcare providers in all phases of research can improve drug development and outcomes for older adults globally. [Extracted from the article]

A recent study conducted by Novartis Pharmaceuticals Corporation explores the selection of a randomization method for a multi-center clinical trial with stochastic recruitment considerations. The study investigates 16 randomization methods and assesses their statistical properties using Monte Carlo simulations. The research concludes that dynamic balancing randomization with carefully chosen maximum tolerated imbalance thresholds could be an effective strategy for trials with competitive patient recruitment policies. This study provides valuable insights for researchers planning multi-center randomized controlled trials. [Extracted from the article]

Researchers from the University of Tokyo have discovered the mechanism of a drug that effectively treats certain types of cancer by targeting a protein modification that silences tumor suppressor genes. Clinical trials have shown that the drug reduces tumor growth in blood cancer and could potentially lead to longer-term treatments for the disease and therapies for other types of cancer with similar underlying causes. The drug, called valemetostat, inhibits the methylation of histone H3, which is associated with the repression of tumor suppressor genes. However, challenges remain, such as the development of resistance to long-term treatment. [Extracted from the article]

A Phase 3 clinical trial led by researchers at the University of California - San Francisco has found that combining testosterone-blocking drugs in patients with relapsed prostate cancer is more effective in preventing the spread of cancer compared to treatment with a single drug. The approach can extend the time between debilitating drug treatments without prolonging the recovery time. The study focused on patients who had surgery for prostate cancer and experienced a relapse detected through a sudden increase in prostate-specific antigen (PSA) levels. The findings support the use of more intensive testosterone-blocking therapy in patients with higher-risk prostate cancer. [Extracted from the article]

A recent study conducted by researchers at Tyumen State Medical University explores the neuroprotective potential of gliflozins, a class of oral antihyperglycemic drugs commonly used in the treatment of type 2 diabetes mellitus. The study found that gliflozins have various pleiotropic properties, including anti-inflammatory effects, reduction of beta-amyloid, improvement of neurotransmission, and anti-acetylcholinesterase effects. These mechanisms contribute to an anti-inflammatory and anti-atherogenic effect, improved cognitive abilities, and a potential improvement in prognosis for patients with Alzheimer's disease. However, further research and clinical trials are needed to establish clear indications for the use of gliflozins in neurology. [Extracted from the article]

A recent study conducted in Mengzi, People's Republic of China, explored the effectiveness and safety of various treatments for drug-induced liver injury (DILI). The researchers conducted a network meta-analysis of 13 liver protective drugs and found that certain interventions, such as MI and compound glycyrrhizin, were effective in minimizing levels of specific enzymes and bilirubin in patients after treatment. Placebo and RT were identified as interventions with the least adverse reactions post-treatment. The study provides valuable insights into the clinical effects of commonly used drugs for the treatment of DILI. [Extracted from the article]

Keywords: Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Health and Medicine EN Clinical Research Clinical Trials and Studies Drugs and Therapies Health and Medicine 2185 2185 1 11/06/23 20231106 NES 231106 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on agriculture is now available. Clinical Research, Clinical Trials and Studies, Drugs and Therapies, Health and Medicine. [Extracted from the article]

Keywords: Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Enzyme Replacement Therapy; Enzymes and Coenzymes; Health and Medicine; Inborn Errors of Metabolism EN Clinical Research Clinical Trials and Studies Drugs and Therapies Enzyme Replacement Therapy Enzymes and Coenzymes Health and Medicine Inborn Errors of Metabolism 1124 1124 1 10/09/23 20231009 NES 231009 2023 OCT 9 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on inborn errors of metabolism have been published. Performing adequate dose-finding in early-phase clinical studies in a well-defined study population, including pediatric subjects, is generally critical to inform dose selection for pivotal trials; alternatively, additional dose exploration can be incorporated as part of a pivotal trial. [Extracted from the article]

For more information on this research see: Evaluation of text summarization techniques in healthcare domain: Pharmaceutical drug feedback. Keywords: Drugs and Therapies; Technology EN Drugs and Therapies Technology 1335 1335 1 10/03/23 20231003 NES 231003 2023 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on technology is now available. [Extracted from the article]

Keywords: Drugs and Therapies; Health Policy; Health and Medicine; Legislation; Pharmaceuticals; Public Health; Smoking Cessation Agents; University of Massachusetts Amherst; Varenicline Therapy EN Drugs and Therapies Health Policy Health and Medicine Legislation Pharmaceuticals Public Health Smoking Cessation Agents University of Massachusetts Amherst Varenicline Therapy 1123 1123 1 09/25/23 20230925 NES 230925 2023 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Nicotine e-cigarettes and two prescription medications that curb symptoms of withdrawal are the most effective stop-smoking aids, according to a comprehensive, multinational review by a team of scientists, including a University of Massachusetts Amherst public health and health policy researcher. Keywords for this news article include: Pharmaceuticals, Legislation, Health Policy, Public Health, Drugs and Therapies, Health and Medicine, Varenicline Therapy, Smoking Cessation Agents, University of Massachusetts Amherst. [Extracted from the article]

According to news reporting originating from Victoria, Australia, by NewsRx correspondents, research stated, "Minimal trauma fractures (MTFs) often occur in older patients with osteoporosis and may be precipitated by falls risk-increasing drugs. Keywords: Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Health and Medicine; Metabolic Bone Diseases and Conditions; Musculoskeletal Diseases and Conditions; Osteoporosis EN Clinical Research Clinical Trials and Studies Drugs and Therapies Health and Medicine Metabolic Bone Diseases and Conditions Musculoskeletal Diseases and Conditions Osteoporosis 1274 1274 1 09/11/23 20230911 NES 230911 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on osteoporosis is now available. [Extracted from the article]

Amsterdam, Netherlands, Europe, Drug Research, Drugs and Therapies, Health and Medicine, Mental Health, Pharmacotherapy, Psychological, Psychology, Psychotherapy, Therapy New Drug Research Study Results from Vrije Universiteit Amsterdam Described (Psychological Treatment of Depression: a Systematic Overview of a "meta-analytic Research Domain") Keywords: Amsterdam; Netherlands; Europe; Drug Research; Drugs and Therapies; Health and Medicine; Mental Health; Pharmacotherapy; Psychological; Psychology; Psychotherapy; Therapy EN Amsterdam Netherlands Europe Drug Research Drugs and Therapies Health and Medicine Mental Health Pharmacotherapy Psychological Psychology Psychotherapy Therapy 1028 1028 1 08/21/23 20230821 NES 230821 2023 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Fresh data on Drug Research are presented in a new report. [Extracted from the article]

Keywords: Rahway; State:New Jersey; United States; North and Central America; Antibodies; Biopharmaceutical Companies; Blood Proteins; Business; Drug Conjugates; Drug Development; Drugs and Therapies; Health and Medicine; Healthcare Biotechnology Companies; Immunoglobulins; Immunology; Proteins EN Rahway State:New Jersey United States North and Central America Antibodies Biopharmaceutical Companies Blood Proteins Business Drug Conjugates Drug Development Drugs and Therapies Health and Medicine Healthcare Biotechnology Companies Immunoglobulins Immunology Proteins 1475 1475 1 07/31/23 20230731 NES 230731 2023 JUL 31 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on Drugs and Therapies - Drug Conjugates is now available. ADCs are a hybrid construct combining, via chemical conjugation, biologic (monoclonal antibody)and small-molecule (drug-linker) moieties into a single drug substance. [Extracted from the article]

Bioinformatics, Biotechnology, Cancer, Centro Nacional de Investigaciones Oncologicas (CNIO), Genetics, Health and Medicine, Information Technology, Oncology Keywords: Bioinformatics; Biotechnology; Cancer; Centro Nacional de Investigaciones Oncologicas (CNIO); Genetics; Health and Medicine; Information Technology; Oncology EN Bioinformatics Biotechnology Cancer Centro Nacional de Investigaciones Oncologicas (CNIO) Genetics Health and Medicine Information Technology Oncology 43 43 1 07/03/23 20230704 NES 230704 2023 JUL 4 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- • Developed by CNIO and the University of Vigo, the PanDrugs2 programme analyses alterations in tumour genes, relates them to existing available drugs, and reports on the most suitable ones • PanDrugs2 handles data on more than 4,600 genes and 14,600 chemical compounds. [Extracted from the article]

Drugs and Therapies, Gastroenterology, Health and Medicine, Pharmacology, Therapy Keywords: Drugs and Therapies; Gastroenterology; Health and Medicine; Pharmacology; Therapy EN Drugs and Therapies Gastroenterology Health and Medicine Pharmacology Therapy 1426 1426 1 06/26/23 20230626 NES 230626 2023 JUN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on pharmacology is now available. [Extracted from the article]

They also proved that the myelin water fraction technique, when focused on the right parts of the brain, could be used to track myelin recovery. In their study, published May 8, 2023, in PNAS, the researchers found that patients with MS who were treated with clemastine experienced modest increases in myelin water, indicating myelin repair. Can this medication reverse MS?. [Extracted from the article]

Keywords: Antiparkinson Agents; Carbidopa; Carbidopa Therapy; Catecholamines; Central Nervous System Agents; Dihydroxyphenylalanine; Dopaminergic Antiparkinsonism Agents; Drugs and Therapies; Health and Medicine; Hydrazines; Levodopa; Levodopa Therapy; Methyldopa Therapy; Organic Chemicals; Pharmaceuticals; Pharmacodynamics EN Antiparkinson Agents Carbidopa Carbidopa Therapy Catecholamines Central Nervous System Agents Dihydroxyphenylalanine Dopaminergic Antiparkinsonism Agents Drugs and Therapies Health and Medicine Hydrazines Levodopa Levodopa Therapy Methyldopa Therapy Organic Chemicals Pharmaceuticals Pharmacodynamics 1305 1305 1 05/15/23 20230515 NES 230515 2023 MAY 15 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on dopaminergic antiparkinsonism agents. Antiparkinson Agents, Carbidopa, Carbidopa Therapy, Catecholamines, Central Nervous System Agents, Dihydroxyphenylalanine, Dopaminergic Antiparkinsonism Agents, Drugs and Therapies, Health and Medicine, Hydrazines, Levodopa, Levodopa Therapy, Methyldopa Therapy, Organic Chemicals, Pharmaceuticals, Pharmacodynamics. [Extracted from the article]

Keywords: Sao Paulo; Brazil; South America; Drug Research; Health and Medicine EN Sao Paulo Brazil South America Drug Research Health and Medicine 1176 1176 1 04/10/23 20230410 NES 230410 2023 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Drug Research are discussed in a new report. Keywords for this news article include: Sao Paulo, Brazil, South America, Drug Research, Health and Medicine, Federal University. Sao Paulo, Brazil, South America, Drug Research, Health and Medicine. [Extracted from the article]